Safety and tolerability of a combined oral contraceptive containing estetrol/drospirenone in real-life clinical practice: An open-label, prospective, multicenter, epidemiological, observational program "Estetiko"
Aim. To evaluate the safety and acceptability of a combined oral contraceptive (COC) containing estetrol 15 mg and drospirenone 3 mg when taken for 6 cycles in real clinical practice. Materials and methods. An open-label prospective multicenter (in 20 cities of the Russian Federation) epidemiolog...
Saved in:
| Main Authors: | Natalia V. Aganezova, Rushania I. Gabidullina |
|---|---|
| Format: | Article |
| Language: | Russian |
| Published: |
IP Berlin A.V.
2025-01-01
|
| Series: | Гинекология |
| Subjects: | |
| Online Access: | https://gynecology.orscience.ru/2079-5831/article/viewFile/684721/199569 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Safety and evidence base of a combined oral contraceptive based on estherol and drospirenone: a brief summary
by: Mekan R. Orazov, et al.
Published: (2024-09-01) -
"Neutrality in everything," or "endocrine-metabolic nocturne" of the combined oral contraceptive based on E4/drospirenone: A review
by: Mekan R. Orazov, et al.
Published: (2025-01-01) -
The perfect molecule for hormonal contraception: Estetrol benefits. A review
by: Elena A. Gorbunova, et al.
Published: (2024-12-01) -
Do hormonal contraceptives increase breast cancer risk? Insights from a 30-year bibliographic analysis
by: Johana I. Rodriguez-Ruiz, et al.
Published: (2025-07-01) -
How have changes in accessibility and public funding influenced contraceptive use among Norwegian adolescents? A cohort study
by: Sunniva Sæbø, et al.
Published: (2024-09-01)